ICICI Direct has given Buy recommendation for Hester Biosciences with a target price of Rs. 2925 in its research report issued on Aug 13, 2021

ICICI Direct’s research report on Hester Biosciences

Hester is one of India’s leading animal healthcare companies & the second largest poultry vaccine manufacturer in the country. It has a strategic presence in 30+ countries with key markets being India, Nepal and Tanzania. It operates through four broad verticals: poultry vaccines, poultry health products, animal vaccines and animal health products Revenue segment wise: poultry healthcare:73%, animal healthcare: 19%, others:8%; by geography: domestic:81%, exports:10%, others:9%

Outlook

We change our view from HOLD to BUY on account of positive impact of expected improvement in exports We value Hester at Rs 2925 (base business at Rs 2809 i.e. 40x P/E on FY23E EPS + NPV of Rs 114 Covaxin DS opportunity)

 

Leave a Reply

Your email address will not be published. Required fields are marked *